EUCTR2013-002223-42-GB进行中（未招募）1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc,
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- •2. Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Male or female, = 18 years of age.
- •4. Weight is = 40 kg at Screening.
- •5. Subject has cancer diagnosed as having metastasized to bone or has multiple myeloma.
- •6. Imaging confirmation of bone metastasis at Screening or within 120 days prior to the Screening visit according to local standard of care (eg, via bone scan, magnetic resonance imaging (MRI), computed tomography (CT) scan, or positron emission tomography-computed tomography (PET-CT) scan).
- •7. Subject is expected to require daily opioid medication throughout the course of the study.
- •8. Subject willing to not use prohibited medications (including NSAIDs) throughout the duration of the study.
- •9. Average Pain Score =5 at Screening for the index bone metastasis cancer pain site.
- •10. Patient’s Global Assessment of Cancer Pain must be fair”, poor” or very poor” at Screening.
- •11. Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at Screening.
- •12. Adequate bone marrow function at Screening as defined in the protocol.
- •13. Adequate renal function at Screening as defined in the protocol.
- •14. Adequate liver function at Screening as defined in the protocol.
- •15. Female subjects of childbearing potential and at risk for pregnancy must agree to use at least one highly effective method of contraception throughout the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous study medication.
- •For the rest of the inclusion criteria, please refer to the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. The subject’s pain is related to an oncologic emergency.
- •2. The subject has brain metastasis or leptomeningeal metastasis.
- •3. The subject’s pain is primarily classified as neuropathic, visceral or unknown in nature, has resulted from prior cancer therapy, is due to infection or is otherwise not predominantly related to a bone metastasis.
- •4. Systemic treatment for the primary malignancy or bone metastasis, including chemotherapy, hormonal treatment (eg, gonadotropin-releasing hormone (GnRH) agonists or antagonists), bisphosphonates and denosumab started within 30 days of the first day of the Baseline Assessment Period.
- •5. Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone metastasis within 30 days of the first day of the Baseline Assessment Period.
- •6. Diagnosis of osteoarthritis of the knee or hip as defined by the American College of Rheumatology (ACR) combined clinical and radiographic criteria.
- •7. Subjects with symptoms and radiographic findings consistent with osteoarthritis in the shoulder.
- •8. History or radiographic evidence of orthopedic conditions that may increase the risk of joint safety conditions during the study as defined in the protocol.
- •9. Signs and symptoms of clinically significant cardiac disease within 6 months of the study as defined in the protocol or subjects with any other cardiovascular illness that in the opinion of the investigator would render a subject unsuitable to participate in the study.
- •10. Subjects with orthostatic hypotension or evidence for an autonomic neuropathy at Screening as defined in the protocol.
- •11. History, diagnosis, or signs and symptoms of clinically significant neurological disease as described in the protocol.
- •12. Planned surgical procedure during the duration of the study
- •13. Subjects considered unfit for surgery as defined in the protocol.
- •For the rest of the exclusion criteria, please refer to the protocol
研究者
相似试验
尚未招募
3 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAZODALIBEP IN PARTICIPANTS WITH SJÖGREN’S SYNDROME WITH MODERATE-TO-SEVERE SYSTEMIC DISEASE ACTIVITYM350 Sicca syndrome [Sjogren]Sicca syndrome [Sjogren]M350PER-050-23Horizon Therapeutics Ireland DAC
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPYEUCTR2013-002223-42-PLPfizer Inc, 235 East 42nd Street, New York, NY 10017155
进行中（未招募）
1 期
Double Blind, Placebo Controlled, Study of the „Pain Killer Efficacy and Safety of Tanezumab (PF 04383119) in Subjects with Cancer Pain mainly Due to Bone Metastasis Receiving Background Opioid TherapyEUCTR2013-002223-42-SKPfizer Inc,155
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPYEUCTR2013-002223-42-ATPfizer Inc, 235 East 42nd Street, New York, NY 10017155
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEEOsteoarthritis of the hip or kneeMedDRA version: 21.1 Level: LLT Classification code 10023476 Term: Knee osteoarthritis System Organ Class: 100000004859MedDRA version: 21.1 Level: LLT Classification code 10020108 Term: Hips osteoarthritis System Organ Class: 100000004859EUCTR2013-004508-21-PTPfizer Inc, 235 East 42nd Street, New York, NY 10017849